3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
6
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Melanoma
44
Uveal Melanoma
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, T-Cell, Cutaneous
6
Lymphoma, Mantle-Cell
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hodgkin Disease
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Large-Cell, Immunoblastic
5
Burkitt Lymphoma
5
Sezary Syndrome
4
Neoplasm Metastasis
4
Myelodysplastic Syndromes
4
Mycosis Fungoides
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Acute
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia
4
Waldenstrom Macroglobulinemia
3
Recurrence
3
Primary Myelofibrosis
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Myeloproliferative Disorders
3
Multiple Myeloma
3
Lung Neoplasms
3
Interventions
pembrolizumab
28
Nivolumab
14
Ipilimumab
7
Cyclophosphamide
7
spartalizumab
6
atezolizumab
4
Interleukin-2
4
fludarabine
3
durvalumab
3
cemiplimab
3
avelumab
3
aldesleukin
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Immune Checkpoint Inhibitors
3
Docetaxel
3
obinutuzumab
2
epacadostat
2
budigalimab
2
bempegaldesleukin
2
Pemetrexed
2
Paclitaxel
2
Leucovorin
2
Carboplatin
2
CTLA-4 Antigen
2
Biopsy
2
vocimagene amiretrorepvec
1
venetoclax
1
utomilumab
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
sargramostim
×
Dermatologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled